Portfolio concentration
As of January 31, 2026 · N-PORT
Holdings
87
Top-10 weight
51.41%
Effective holdings
?
The number of equal-weight positions that would produce this portfolio's concentration (1 ÷ Herfindahl index). A 500-stock fund dominated by a few mega-caps might have only ~100 effective holdings.
21
Crowding
?
The value-weighted average number of funds that also own this fund's positions. High = consensus/crowded picks; low = holdings few other funds own.
715.9
Holdings
As of January 31, 2026 · N-PORT| # | Security | Ticker | Shares | Value | % of fund |
|---|---|---|---|---|---|
| 1 | ABBVIE INC | — | 1,389,580 | $309.89M | 16.61% |
| 2 | GILEAD SCIENCES INC | — | 864,100 | $122.66M | 6.57% |
| 3 | ALNYLAM PHARMACEUTICALS INC | — | 277,186 | $93.71M | 5.02% |
| 4 | Ascendis Pharma A/S | — | 370,625 | $83.80M | 4.49% |
| 5 | COGENT BIOSCIENCES INC | — | 1,988,418 | $71.40M | 3.83% |
| 6 | ARGENX SE SPONSORED ADR | — | 81,000 | $68.08M | 3.65% |
| 7 | Fidelity Securities Lending Cash Central Fund | — | 66,938,144 | $66.94M | 3.59% |
| 8 | INSMED INC | — | 412,300 | $64.68M | 3.47% |
| 9 | VIRIDIAN THERAPEUTICS INC | — | 1,782,464 | $58.82M | 3.15% |
| 10 | BIOGEN INC | — | 294,100 | $52.91M | 2.84% |
| 11 | AMGEN INC | — | 150,703 | $51.52M | 2.76% |
| 12 | VAXCYTE INC | — | 796,329 | $42.66M | 2.29% |
| 13 | STRUCTURE THERAPEUTICS INC ADR | — | 481,200 | $42.56M | 2.28% |
| 14 | NUVALENT INC-A | — | 412,264 | $42.42M | 2.27% |
| 15 | DIANTHUS THERAPEUTICS INC | — | 730,062 | $38.98M | 2.09% |
| 16 | AMYLYX PHARMACEUTICALS INC | — | 2,433,200 | $34.77M | 1.86% |
| 17 | MODERNA INC | — | 674,300 | $29.72M | 1.59% |
| 18 | APOGEE THERAPEUTICS INC | — | 452,639 | $29.65M | 1.59% |
| 19 | XENON PHARMACEUTICALS INC | — | 710,758 | $29.15M | 1.56% |
| 20 | CRINETICS PHARMACEUTICALS INC | — | 544,470 | $27.19M | 1.46% |
| 21 | PRAXIS PRECISION MEDICINES INC | — | 86,400 | $27.13M | 1.45% |
| 22 | SCHOLAR ROCK HOLDING CORP | — | 582,368 | $25.82M | 1.38% |
| 23 | ORUKA THERAPEUTICS INC | — | 710,786 | $24.33M | 1.30% |
| 24 | SPYRE THERAPEUTICS INC | — | 749,342 | $23.96M | 1.28% |
| 25 | UCB SA | — | 75,800 | $22.95M | 1.23% |
| 26 | UNIQURE N.V. | — | 991,600 | $22.53M | 1.21% |
| 27 | UPSTREAM BIO INC | — | 691,003 | $21.48M | 1.15% |
| 28 | ROIVANT SCIENCES LTD | — | 976,200 | $21.11M | 1.13% |
| 29 | NATERA INC | — | 89,400 | $20.66M | 1.11% |
| 30 | OLEMA PHARMACEUTICALS INC | — | 782,800 | $20.13M | 1.08% |
| 31 | VIKING THERAPEUTICS INC | — | 647,387 | $18.80M | 1.01% |
| 32 | NEWAMSTERDAM PHARMA COMPANY NV | — | 586,400 | $18.25M | 0.98% |
| 33 | CYTOKINETICS INC | — | 283,071 | $17.89M | 0.96% |
| 34 | KYMERA THERAPEUTICS INC | — | 231,700 | $16.84M | 0.90% |
| 35 | JADE BIOSCIENCES INC | — | 894,343 | $13.96M | 0.75% |
| 36 | CG ONCOLOGY INC | — | 248,900 | $12.96M | 0.69% |
| 37 | RHYTHM PHARMACEUTICALS INC | — | 126,200 | $12.94M | 0.69% |
| 38 | ENLIVEN THERAPEUTICS INC | — | 474,262 | $12.54M | 0.67% |
| 39 | ZENAS BIOPHARMA INC | — | 629,316 | $11.56M | 0.62% |
| 40 | DISC MEDICINE INC | — | 142,322 | $11.00M | 0.59% |
| 41 | ARCELLX INC | — | 142,900 | $9.76M | 0.52% |
| 42 | STOKE THERAPEUTICS INC | — | 317,700 | $9.64M | 0.52% |
| 43 | TRAVERE THERAPEUTICS INC | — | 301,200 | $9.36M | 0.50% |
| 44 | MINERALYS THERAPEUTICS INC | — | 266,800 | $8.24M | 0.44% |
| 45 | CYTOMX THERAPEUTICS INC | — | 1,350,251 | $7.68M | 0.41% |
| 46 | ANAPTYSBIO INC | — | 148,400 | $7.04M | 0.38% |
| 47 | SOLENO THERAPEUTICS INC | — | 181,000 | $6.98M | 0.37% |
| 48 | CELLDEX THERAPEUTICS INC | — | 275,652 | $6.78M | 0.36% |
| 49 | REZOLUTE INC | — | 1,985,100 | $6.63M | 0.36% |
| 50 | ANNEXON INC | — | 1,005,200 | $6.27M | 0.34% |
1 / 2
Next ›
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.